comparemela.com

Page 13 - David Adlington News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Declining covid tests and costs weigh on lab chain Synlab

The end of the Corona wave is currently casting a long shadow over the laboratory industry. The laboratory chain Synlab also continues to struggle with the sharp decline in testing for the virus. In.

SYNLAB : JP Morgan reiterates its Neutral rating

David Adlington from JP Morgan retains his Neutral opinion on the stock. The target price is unchanged at EUR 9.30.

Fresenius Medical Care AG & Co KGaA (NYSE:FMS) Q2 2023 Earnings Call Transcript

FMC FRESENIUS MEDICAL CARE AG & CO KGAA : JP Morgan keeps a Sell rating

David Adlington from JP Morgan retains his negative opinion on the stock with a Sell rating. The target price is being increased from EUR 28.60 to EUR 38.00.

FRESENIUS SE : JP Morgan reaffirms its Neutral rating

David Adlington from JP Morgan retains his Neutral opinion on the stock. The target price remains set at EUR 29.60.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.